Investigator-led SwissNET registry analysis showed longer real-world progression-free and overall survival for patients re-treated with 177Lu-edotreotide compared to those receiving non-radiopharmaceutical systemic therapyPhase 3 COMPETE trial dosimetry analysis demonstrated favorable tumor-to-kidney absorbed dose ratio with low intra-patient variability